Endocrine
Glucagonoma
Also known as Glucagon-secreting pancreatic tumor, necrolytic migratory erythema syndrome
Glucagonoma is a rare functional pancreatic neuroendocrine tumour arising from alpha cells that secrete excessive glucagon, producing a distinctive clinical syndrome dominated by necrolytic migratory erythema, a characteristic skin rash, al
0
studies recruiting now
as of 7 Sept 2026
34
studies registered in total
as of 7 Sept 2026
0
countries with a recruiting site
as of 7 Sept 2026
None
recruiting study posted to date
among recruiting studies
Recruiting trials
No recruiting trial found right now.
34 studies are registered for Glucagonoma, but none was recruiting as of 7 Sept 2026. Here is what is still worth doing.
Keep watching
Get an email when a new Glucagonoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: NANETS Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Glucagonoma
Glucagonoma is a rare functional pancreatic neuroendocrine tumour arising from alpha cells that secrete excessive glucagon, producing a distinctive clinical syndrome dominated by necrolytic migratory erythema, a characteristic skin rash, alongside diabetes mellitus, hypoaminoacidaemia, weight loss, anaemia, and venous thrombosis. The rash, which migrates and heals centrally while expanding peripherally and frequently affects the perineum, lower abdomen, and extremities, is often the presenting feature that leads to diagnosis. More than 60–70% of glucagonomas are malignant at presentation, with hepatic metastases frequently present, rendering curative resection impossible in many patients.
Common clinical features
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Glucagonoma. Not eligibility rules; those are set by each study.
- Fasting serum glucagon level above 500 pg/mL, combined with imaging evidence of a pancreatic mass and characteristic symptoms, is the standard diagnostic threshold used for trial enrolment.
- Somatostatin receptor scintigraphy or 68Ga-DOTATATE PET scan demonstrating receptor positivity is required for trials of somatostatin analogues or peptide receptor radionuclide therapy (PRRT).
- Thromboprophylaxis and nutritional status (albumin, amino acid levels) are assessed at baseline screening; patients with active deep vein thrombosis or severe malnutrition may need stabilisation before enrolment.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).